Enhanced oral absorption and therapeutic effect of acetylpuerarin based on D-α-tocopheryl polyethylene glycol 1000 succinate nanoemulsions

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3413-3423

  Sun, Deqing ^a,b   Wei, Xinbing ^a   Xue, Xia ^b   Fang, Zengjun ^b   Ren, Manru ^a   Lou, Haiyan ^a   Zhang, Xiumei ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Absorption; Chylomicron flow blocking rat model; Lipid digestion; Lymphatic transport; Nanoemulsions; TPGS; Transient middle cerebral artery occlusion rat model

Indexed keywords

ACETYLPUERARIN; ALPHA TOCOPHEROL DERIVATIVE; DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; FLAVONOID; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; EMULSION; ISOFLAVONE DERIVATIVE; NANOMATERIAL; TOCOFERSOLAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; DRUG STABILITY; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NANOENCAPSULATION; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; PRECIPITATION; RAT; REPERFUSION INJURY; SOLUBILIZATION; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CEREBRAL ARTERY DISEASE; CHEMISTRY; DRUG EFFECTS; EMULSION; GASTROINTESTINAL ABSORPTION; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHARMACOKINETICS; PHARMACOLOGY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; EMULSIONS; INFARCTION, MIDDLE CEREBRAL ARTERY; ISOFLAVONES; MALE; NANOSTRUCTURES; ORAL MUCOSAL ABSORPTION; RATS; RATS, WISTAR; VITAMIN E;

EID: 84904660041     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S63777     Document Type: Article

References (43)

1. Hu SS, Kong LZ, Gao RL, et al; Editorial Board. Outline of the report on cardiovascular disease in China, 2010. Biomed Environ Sci. 2012; 25(3):251-256.
2. Hou L, Wei X, Li X, et al. Protective effects of acetylpuerar in on foca brain ischemia-reperfusion in jury in rats. China Pharm J.2007;42(19): 1469-1472.
3. Weiping S, Changqing Y, Yanjing C, Zhiguo Z, Xiangzheng K. Selfassembly of an amphiphilic derivative of chitosan and micellar solubilization of puerarin. Colloids Surf B Biointerfaces. 2006;48(1):13-16.
4. Zeng X, Chen H, Zheng Y, et al. Enhanced adsorption of puerarin onto a novel hydrophilic and polar modified post-crosslinked resin from aqueous solution. J Colloid Interface Sci. 2012;385(1):166-173.
5. Hou L, Zhang XM, Wei XB. Protective effects of Compounds N-2211 on focal brain ischemia-reperfusion injury in rats. Qilu Pharm Affairs. 2004;3:52-54.
6. Liu R, Wei XB, Zhang XM. Effects of acetylpuerarin on hippocampal neurons and intracellular free calcium subjected to oxygenglucose deprivation/reperfusion in primary culture. Brain Res. 2007; 1147:95-104.
7. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013; 170(1):15-40.
8. Wang Y, Ma Y, Zheng Y, et al. In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity. Int J Pharm. 2013;441(1-2):728-735.
9. Guo D, Yang D, Chen S. Pharmacokinetic investigation of Pur and derivatives in rats. J Shaanxi Tradit Chin Med. 2008;31(52):52-54.
10. Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci. 2013;49(2): 175-186
11. Xiang Y, Liu S, Wei C, et al. In vivo pharmacokinetic study of hexaacetylpurerarin in rats. Chin Tradit Herbal Drugs. 2012;43(11): 2247-2249.
12. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond). 2012;7(10):1577-1590.
13. Nazarzadeh E, Anthonypillai T, Sajjadi S. On the growth mechanisms of nanoemulsions. J Colloid Interface Sci. 2013;397:154-162.
14. Mei L, Zhang Z, Zhao L, et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 2013;65(6): 880-890.
15. An HZ, Helgeson ME, Doyle PS. Nanoemulsion composite microgels for orthogonal encapsulation and release. Adv Mater. 2012;24(28): 3838-3844, 3895.
16. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163(1):34-45.
17. Hirsjärvi S, Dufort S, Gravier J, et al. Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models. Nanomedicine. 2013;9(3):375-387.
18. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33(19):4889-4906.
19. Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm. 2010;7(3):642-651.
20. Collnot EM, Baldes C, Wempe MF, et al. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm. 2007;4(3):465-474.
21. Mi Y, Zhao J, Feng SS. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release. 2013;169(3): 185-192.
22. He W, Lu Y, Qi J, Chen L, Hu F, Wu W. Nanoemulsion-templated shell-crosslinked nanocapsules as drug delivery systems. Int J Pharm. 2013;445(1-2):69-78.
23. Alayoubi AY, Anderson JF, Satyanarayanajois SD, Sylvester PW, Nazzal S. Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcenoma cells. Eur J Pharm Sci. 2012;48(3):385-392.
24. Doh HJ, Jung Y, Balakrishnan P, Cho HJ, Kim DD. A novel lipid nanoemulsion system for improved permeation of granisetron. Colloids Surf B Biointerfaces. 2013;101:475-480.
25. Han SF, Yao TT, Zhang XX, et al. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Int J Pharm. 2009;379(1):18-24.
26. Lian R, Lu Y, Qi J, et al. Silymarin glyceryl monooleate/poloxamer 407 liquid crystalline matrices: physical characterization and enhanced oral bioavailability. AAPS Pharm Sci Tech. 2011;12(4):1234-1240.
27. Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J Pharm Sci. 2001;14(3):237-244.
28. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-248.
29. Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24(4):381-388.
30. Lind ML, Jacobsen J, Holm R, Müllertz A. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80. Eur J Pharm Sci. 2008; 35(3):211-218.
31. Wang ZY, Wei XB, Chen L, et al. Neuroprotective effects of hydroxyethylpuerarin against focal cerebral ischemia-reperfusion in rats. Chin J Physiol. 2007;50(5):211-216.
32. He W, Tan Y, Tian Z, Chen L, Hu F, Wu W. Food protein-stabilized nanoemulsions as potential delivery systems for poorly water-soluble drugs: preparation, in vitro characterization, and pharmacokinetics in rats. Int J Nanomedicine. 2011;6:521-533.
33. Lee SJ, Choi SJ, Li Y, Decker EA, McClements DJ. Protein-stabilized nanoemulsions and emulsions: comparison of physicochemical stability, lipid oxidation, and lipase digestibility. J Agric Food Chem. 2011; 59(1):415-427.
34. Akkar A, Müller RH. Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm. 2003;56(1):29-36.
35. Llinàs M, Calderó G, García-Celma MJ, Patti A, Solans C. New insights on the mechanisms of drug release from highly concentrated emulsions. J Colloid Interface Sci. 2013;394:337-345.
36. Washington C, Evans K. Release rate measurements of model hydrophobic solutes from submicron triglyceride emulsions. J Control Release. 1995;33(3):383-390.
37. Li Y, Hu M, Du Y, McClements DJ. Controlling lipid nanoemulsion digestion using nanolaminated biopolymer coatings. J Microencapsul. 2011;28(3):166-175.
38. Porter CJ, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004;21(8):1405-1412.
39. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60(6):673-691.
40. Simovic S, Heard P, Hui H, et al. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol Pharm. 2009;6(3):861-872.
41. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm. 2006;63(3):288-294.
42. Fan Z, Wu J, Fang X, Sha X. A new function of Vitamin E-TPGS in the intestinal lymphatic transport of lipophilic drugs: enhancing the secretion of chylomicrons. Int J Pharm. 2013;445(1-2):141-147.
43. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129(1):1-10